{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T22:26:31Z","timestamp":1787005591332,"version":"build-2736575974"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"34","license":[{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2026,9,8]]},"DOI":"10.1038\/s41388-026-03901-x","type":"journal-article","created":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T15:14:44Z","timestamp":1784214884000},"page":"3511-3524","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Multiparatopic antibodies overcome tyrosine kinase inhibitor resistance by inducing lysosomal degradation of EGFR mutants"],"prefix":"10.1038","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8188-157X","authenticated-orcid":false,"given":"Chunjie","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiacheng","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7868-6917","authenticated-orcid":false,"given":"Dingrui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yafei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0739-197X","authenticated-orcid":false,"given":"Wanyinhui","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinuo","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunling","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingbin","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sitong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weirui","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaoji","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7040-6104","authenticated-orcid":false,"given":"Deli","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,16]]},"reference":[{"key":"3901_CR1","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ijrobp.2003.11.041","volume":"59","author":"RS Herbst","year":"2004","unstructured":"Herbst RS. Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys. 2004;59:21\u20136.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"3901_CR2","doi-asserted-by":"publisher","first-page":"815","DOI":"10.2174\/1568026620666200303123102","volume":"20","author":"DA Sabbah","year":"2020","unstructured":"Sabbah DA, Hajjo R, Sweidan K. Review on Epidermal Growth Factor Receptor (EGFR) Structure, Signaling Pathways, Interactions, and Recent Updates of EGFR Inhibitors. Curr Top Med Chem. 2020;20:815\u201334.","journal-title":"Curr Top Med Chem"},{"key":"3901_CR3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/1878-0261.12155","volume":"12","author":"S Sigismund","year":"2018","unstructured":"Sigismund S, Avanzato D, Lanzetti L. Emerging functions of the EGFR in cancer. Mol Oncol. 2018;12:3\u201320.","journal-title":"Mol Oncol"},{"key":"3901_CR4","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41568-020-00322-0","volume":"21","author":"S Kumagai","year":"2021","unstructured":"Kumagai S, Koyama S, Nishikawa H. Antitumour immunity regulated by aberrant ERBB family signalling. Nat Rev Cancer. 2021;21:181\u201397.","journal-title":"Nat Rev Cancer"},{"key":"3901_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drup.2018.11.002","volume":"42","author":"A Leonetti","year":"2019","unstructured":"Leonetti A, Assaraf YG, Veltsista PD, El Hassouni B, Tiseo M, Giovannetti E. MicroRNAs as a drug resistance mechanism to targeted therapies in EGFR-mutated NSCLC: Current implications and future directions. Drug Resistance Updates. 2019;42:1\u201311.","journal-title":"Drug Resistance Updates"},{"key":"3901_CR6","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1038\/nrc2947","volume":"10","author":"W Pao","year":"2010","unstructured":"Pao W, Chmielecki J. Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat Rev Cancer. 2010;10:760\u201374.","journal-title":"Nat Rev Cancer"},{"key":"3901_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2015.9","volume":"1","author":"C Gridelli","year":"2015","unstructured":"Gridelli C, Rossi A, Carbone DP, Guarize J, Karachaliou N, Mok T, et al. Non-small-cell lung cancer. Nat Rev Dis Prim. 2015;1:15009.","journal-title":"Nat Rev Dis Prim"},{"key":"3901_CR8","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1016\/S0959-8049(96)00243-2","volume":"32","author":"S Fujino","year":"1996","unstructured":"Fujino S, Enokibori T, Tezuka N, Asada Y, Inoue S, Kato H, et al. A comparison of epidermal growth factor receptor levels and other prognostic parameters in non-small cell lung cancer. Eur J Cancer. 1996;32:2070\u20134.","journal-title":"Eur J Cancer"},{"key":"3901_CR9","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/nrc2088","volume":"7","author":"SV Sharma","year":"2007","unstructured":"Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer. 2007;7:169\u201381.","journal-title":"Nat Rev Cancer"},{"key":"3901_CR10","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1038\/s41586-021-03898-1","volume":"597","author":"JP Robichaux","year":"2021","unstructured":"Robichaux JP, Le X, Vijayan RSK, Hicks JK, Heeke S, Elamin YY, et al. Structure-based classification predicts drug response in EGFR-mutant NSCLC. Nature. 2021;597:732\u20137.","journal-title":"Nature"},{"key":"3901_CR11","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1056\/NEJMct0807960","volume":"364","author":"VD Cataldo","year":"2011","unstructured":"Cataldo VD, Gibbons DL, P\u00e9rez-Soler R, Quint\u00e1s-Cardama A. Treatment of non\u2013small-cell lung cancer with erlotinib or gefitinib. New Engl J Med. 2011;364:947\u201355.","journal-title":"New Engl J Med"},{"key":"3901_CR12","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S1470-2045(14)71173-8","volume":"16","author":"JC-H Yang","year":"2015","unstructured":"Yang JC-H, Wu Y-L, Schuler M, Sebastian M, Popat S, Yamamoto N, et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol. 2015;16:141\u201351.","journal-title":"Lancet Oncol"},{"key":"3901_CR13","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s40164-016-0052-3","volume":"5","author":"D Berz","year":"2016","unstructured":"Berz D, Raymond VM, Garst JH, Erlander MG. Non-invasive urine testing of EGFR activating mutation and T790M resistance mutation in non-small cell lung cancer. Exp Hematol Oncol. 2016;5:24.","journal-title":"Exp Hematol Oncol"},{"key":"3901_CR14","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.apsb.2015.07.001","volume":"5","author":"L Huang","year":"2015","unstructured":"Huang L, Fu L. Mechanisms of resistance to EGFR tyrosine kinase inhibitors. Acta Pharmaceut Sin B. 2015;5:390\u2013401.","journal-title":"Acta Pharmaceut Sin B"},{"key":"3901_CR15","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1056\/NEJMoa044238","volume":"352","author":"S Kobayashi","year":"2005","unstructured":"Kobayashi S, Boggon TJ, Dayaram T, J\u00e4nne PA, Kocher O, Meyerson M. et al. EGFR Mutation and resistance of non\u2013small-cell lung cancer to gefitinib. New Engl J Med. 2005;352:786\u201392.","journal-title":"New Engl J Med"},{"key":"3901_CR16","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJMoa1913662","volume":"382","author":"SS Ramalingam","year":"2020","unstructured":"Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, et al. Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. N Engl J Med. 2020;382:41\u201350.","journal-title":"N Engl J Med"},{"key":"3901_CR17","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","volume":"378","author":"J-C Soria","year":"2018","unstructured":"Soria J-C, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KiH, et al. Osimertinib in Untreated EGFR-Mutated Advanced Non\u2013Small-Cell Lung Cancer. N Engl J Med. 2018;378:113\u201325.","journal-title":"N Engl J Med"},{"key":"3901_CR18","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1038\/nature08622","volume":"462","author":"W Zhou","year":"2009","unstructured":"Zhou W, Ercan D, Chen L, Yun C-H, Li D, Capelletti M, et al. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature. 2009;462:1070\u20134.","journal-title":"Nature"},{"key":"3901_CR19","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/nm.3854","volume":"21","author":"KS Thress","year":"2015","unstructured":"Thress KS, Paweletz CP, Felip E, Cho BC, Stetson D, Dougherty B, et al. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non\u2013small cell lung cancer harboring EGFR T790M. Nat Med. 2015;21:560\u20132.","journal-title":"Nat Med"},{"key":"3901_CR20","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1001\/jamaoncol.2015.1066","volume":"1","author":"HA Yu","year":"2015","unstructured":"Yu HA, Tian SK, Drilon AE, Borsu L, Riely GJ, Arcila ME, et al. Acquired Resistance of EGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor: Emergence of a Third Mutation (C797S) in the EGFR Tyrosine Kinase Domain. JAMA Oncol. 2015;1:982\u20134.","journal-title":"JAMA Oncol"},{"key":"3901_CR21","doi-asserted-by":"publisher","first-page":"3924","DOI":"10.1158\/1078-0432.CCR-15-0560","volume":"21","author":"MJ Niederst","year":"2015","unstructured":"Niederst MJ, Hu H, Mulvey HE, Lockerman EL, Garcia AR, Piotrowska Z. et al. The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies. Clin Cancer Res. 2015;21:3924\u201333.","journal-title":"Clin Cancer Res"},{"key":"3901_CR22","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1093\/annonc\/mdv319","volume":"26","author":"D Planchard","year":"2015","unstructured":"Planchard D, Loriot Y, Andr\u00e9 F, Gobert A, Auger N, Lacroix L, et al. EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients. Ann Oncol. 2015;26:2073\u20138.","journal-title":"Ann Oncol"},{"key":"3901_CR23","doi-asserted-by":"publisher","first-page":"3929","DOI":"10.21037\/tcr-24-406","volume":"13","author":"C Su","year":"2024","unstructured":"Su C, Sun SY. Fourth-generation epidermal growth factor receptor-tyrosine kinases inhibitors: hope and challenges. Transl Cancer Res. 2024;13:3929\u201334.","journal-title":"Transl Cancer Res"},{"key":"3901_CR24","doi-asserted-by":"publisher","first-page":"102824","DOI":"10.1016\/j.ctrv.2024.102824","volume":"130","author":"C Corvaja","year":"2024","unstructured":"Corvaja C, Passaro A, Attili I, Aliaga PT, Spitaleri G, Signore ED. et al. Advancements in fourth-generation EGFR TKIs in EGFR-mutant NSCLC: Bridging biological insights and therapeutic development. Cancer Treatment Rev. 2024;130:102824.","journal-title":"Cancer Treatment Rev"},{"key":"3901_CR25","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","volume":"21","author":"M B\u00e9k\u00e9s","year":"2022","unstructured":"B\u00e9k\u00e9s M, Langley DR, Crews CM. PROTAC targeted protein degraders: the past is prologue. Nat Rev Drug Discov. 2022;21:181\u2013200.","journal-title":"Nat Rev Drug Discov"},{"key":"3901_CR26","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41568-025-00817-8","volume":"25","author":"M Hinterndorfer","year":"2025","unstructured":"Hinterndorfer M, Spiteri VA, Ciulli A, Winter GE. Targeted protein degradation for cancer therapy. Nat Rev Cancer. 2025;25:493\u2013516.","journal-title":"Nat Rev Cancer"},{"key":"3901_CR27","doi-asserted-by":"publisher","first-page":"8554","DOI":"10.1073\/pnas.141230798","volume":"98","author":"KM Sakamoto","year":"2001","unstructured":"Sakamoto KM, Kim KB, Kumagai A, Mercurio F, Crews CM, Deshaies RJ. Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation. Proc Natl Acad Sci USA. 2001;98:8554\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3901_CR28","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1016\/j.cell.2017.10.033","volume":"171","author":"D Clift","year":"2017","unstructured":"Clift D, McEwan WA, Labzin LI, Konieczny V, Mogessie B, James LC, et al. A Method for the Acute and Rapid Degradation of Endogenous Proteins. Cell. 2017;171:1692\u2013706.e1618.","journal-title":"Cell"},{"key":"3901_CR29","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/s41586-020-2545-9","volume":"584","author":"SM Banik","year":"2020","unstructured":"Banik SM, Pedram K, Wisnovsky S, Ahn G, Riley NM, Bertozzi CR. Lysosome-targeting chimaeras for degradation of extracellular proteins. Nature. 2020;584:291\u20137.","journal-title":"Nature"},{"key":"3901_CR30","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1038\/s41589-021-00770-1","volume":"17","author":"G Ahn","year":"2021","unstructured":"Ahn G, Banik SM, Miller CL, Riley NM, Cochran JR, Bertozzi CR. LYTACs that engage the asialoglycoprotein receptor for targeted protein degradation. Nat Chem Biol. 2021;17:937\u201346.","journal-title":"Nat Chem Biol"},{"key":"3901_CR31","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/s41587-022-01456-2","volume":"41","author":"K Pance","year":"2023","unstructured":"Pance K, Gramespacher JA, Byrnes JR, Salangsang F, Serrano J-AC, Cotton AD, et al. Modular cytokine receptor-targeting chimeras for targeted degradation of cell surface and extracellular proteins. Nat Biotechnol. 2023;41:273\u201381.","journal-title":"Nat Biotechnol"},{"key":"3901_CR32","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1038\/s41586-024-07948-2","volume":"638","author":"B Huang","year":"2025","unstructured":"Huang B, Abedi M, Ahn G, Coventry B, Sappington I, Tang C, et al. Designed endocytosis-inducing proteins degrade targets and amplify signals. Nature. 2025;638:796\u2013804.","journal-title":"Nature"},{"key":"3901_CR33","doi-asserted-by":"publisher","first-page":"E973","DOI":"10.1152\/ajpendo.90857.2008","volume":"296","author":"JV Abella","year":"2009","unstructured":"Abella JV, Park M. Breakdown of endocytosis in the oncogenic activation of receptor tyrosine kinases. Am J Physiol Endocrinol Metab. 2009;296:E973\u201384.","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"3901_CR34","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1126\/science.2305263","volume":"247","author":"A Wells","year":"1990","unstructured":"Wells A, Welsh JB, Lazar CS, Wiley HS, Gill GN, Rosenfeld MG. Ligand-induced transformation by a noninternalizing epidermal growth factor receptor. Science. 1990;247:962\u20134.","journal-title":"Science"},{"key":"3901_CR35","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.ccell.2015.12.008","volume":"29","author":"JY Li","year":"2016","unstructured":"Li JY, Perry SR, Muniz-Medina V, Wang X, Wetzel LK, Rebelatto MC, et al. A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy. Cancer Cell. 2016;29:117\u201329.","journal-title":"Cancer Cell"},{"key":"3901_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23948-6","volume":"12","author":"F Kast","year":"2021","unstructured":"Kast F, Schwill M, St\u00fcber JC, Pfundstein S, Nagy-Davidescu G, Rodr\u00edguez JMM, et al. Engineering an anti-HER2 biparatopic antibody with a multimodal mechanism of action. Nat Commun. 2021;12:3790.","journal-title":"Nat Commun"},{"key":"3901_CR37","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.abb.2012.03.005","volume":"526","author":"C Kelton","year":"2012","unstructured":"Kelton C, Wesolowski JS, Soloviev M, Schweickhardt R, Fischer D, Kurosawa E, et al. Anti-EGFR biparatopic-SEED antibody has enhanced combination-activity in a single molecule. Arch Biochem Biophys. 2012;526:219\u201325.","journal-title":"Arch Biochem Biophys"},{"key":"3901_CR38","doi-asserted-by":"publisher","first-page":"3825","DOI":"10.1073\/pnas.83.11.3825","volume":"83","author":"H Sunada","year":"1986","unstructured":"Sunada H, Magun BE, Mendelsohn J, MacLeod CL. Monoclonal antibody against epidermal growth factor receptor is internalized without stimulating receptor phosphorylation. Proc Natl Acad Sci. 1986;83:3825\u20139.","journal-title":"Proc Natl Acad Sci"},{"key":"3901_CR39","doi-asserted-by":"publisher","DOI":"10.3390\/cells11142201","author":"S Nishihara","year":"2022","unstructured":"Nishihara S, Yamaoka T, Ishikawa F, Ohmori T, Ando K, Kusumoto S, et al. Diverse Mechanisms of Resistance against Osimertinib, a Third-Generation EGFR-TKI, in Lung Adenocarcinoma Cells with an EGFR-Activating Mutation. Cells. 2022. https:\/\/doi.org\/10.3390\/cells11142201.","journal-title":"Cells"},{"key":"3901_CR40","doi-asserted-by":"publisher","unstructured":"R\u00edos-Hoyo A, Moliner L, Arriola E. Acquired Mechanisms of Resistance to Osimertinib\u2014The Next Challenge. Cancers 2022; https:\/\/doi.org\/10.3390\/cancers14081931.","DOI":"10.3390\/cancers14081931"},{"key":"3901_CR41","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1126\/science.abc7520","volume":"369","author":"TF Rogers","year":"2020","unstructured":"Rogers TF, Zhao F, Huang D, Beutler N, Burns A, He W-t, et al. Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model. Science. 2020;369:956\u201363.","journal-title":"Science"},{"key":"3901_CR42","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1093\/protein\/gzw040","volume":"29","author":"T Schlothauer","year":"2016","unstructured":"Schlothauer T, Herter S, Koller CF, Grau-Richards S, Steinhart V, Spick C, et al. Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions. Protein Eng, Des Select. 2016;29:457\u201366.","journal-title":"Protein Eng, Des Select"},{"key":"3901_CR43","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1146\/annurev-biochem-081820-092427","volume":"90","author":"M von Zastrow","year":"2021","unstructured":"von Zastrow M, Sorkin A. Mechanisms for Regulating and Organizing Receptor Signaling by Endocytosis. Annu Rev Biochem. 2021;90:709\u201337.","journal-title":"Annu Rev Biochem"},{"key":"3901_CR44","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1152\/physrev.00005.2011","volume":"92","author":"S Sigismund","year":"2012","unstructured":"Sigismund S, Confalonieri S, Ciliberto A, Polo S, Scita G, Di Fiore PP. Endocytosis and Signaling: Cell Logistics Shape the Eukaryotic Cell Plan. Physiol Rev. 2012;92:273\u2013366.","journal-title":"Physiol Rev"},{"key":"3901_CR45","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.249318","volume":"134","author":"M Li","year":"2021","unstructured":"Li M, Yu Y. Innate immune receptor clustering and its role in immune regulation. J Cell Sci. 2021;134:jcs249318.","journal-title":"J Cell Sci"},{"key":"3901_CR46","doi-asserted-by":"publisher","DOI":"10.1002\/smll.202503543","volume":"21","author":"CM Dom\u00ednguez","year":"2025","unstructured":"Dom\u00ednguez CM, Niemeyer CM. Clustering of Membrane Receptors: Insights from DNA Origami-Based Approaches. Small. 2025;21:2503543.","journal-title":"Small"},{"key":"3901_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-36496-y","volume":"14","author":"D Paul","year":"2023","unstructured":"Paul D, Stern O, Vallis Y, Dhillon J, Buchanan A, McMahon H. Cell surface protein aggregation triggers endocytosis to maintain plasma membrane proteostasis. Nat Commun. 2023;14:947.","journal-title":"Nat Commun"},{"key":"3901_CR48","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","volume":"26","author":"ME Keir","year":"2008","unstructured":"Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and Its Ligands in Tolerance and Immunity. Annu Rev Immunol. 2008;26:677\u2013704.","journal-title":"Annu Rev Immunol"},{"key":"3901_CR49","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/nri2326","volume":"8","author":"W Zou","year":"2008","unstructured":"Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol. 2008;8:467\u201377.","journal-title":"Nat Rev Immunol"},{"key":"3901_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-87216-9","volume":"11","author":"B Cherif","year":"2021","unstructured":"Cherif B, Triki H, Charfi S, Bouzidi L, Kridis WB, Khanfir A, et al. Immune checkpoint molecules B7-H6 and PD-L1 co-pattern the tumor inflammatory microenvironment in human breast cancer. Sci Rep. 2021;11:7550.","journal-title":"Sci Rep"},{"key":"3901_CR51","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1016\/S0140-6736(16)00700-5","volume":"387","author":"EF Smit","year":"2016","unstructured":"Smit EF, van den Heuvel MM. PD-L1 in non-small-cell lung cancer: the third target for immunotherapy. Lancet. 2016;387:1795\u20136.","journal-title":"Lancet"},{"key":"3901_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellin.2024.100146","volume":"3","author":"R Liu","year":"2024","unstructured":"Liu R, Li H-F, Li S. PD-1-mediated inhibition of T cell activation: Mechanisms and strategies for cancer combination immunotherapy. Cell Insight. 2024;3:100146.","journal-title":"Cell Insight"},{"key":"3901_CR53","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1200\/JCO.2009.24.7049","volume":"28","author":"D Jackman","year":"2009","unstructured":"Jackman D, Pao W, Riely GJ, Engelman JA, Kris MG, J\u00e4nne PA, et al. Clinical Definition of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non\u2013Small-Cell Lung Cancer. J Clin Oncol. 2009;28:357\u201360.","journal-title":"J Clin Oncol"},{"key":"3901_CR54","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-018-0793-1","volume":"17","author":"Q Liu","year":"2018","unstructured":"Liu Q, Yu S, Zhao W, Qin S, Chu Q, Wu K. EGFR-TKIs resistance via EGFR-independent signaling pathways. Mol Cancer. 2018;17:53.","journal-title":"Mol Cancer"},{"key":"3901_CR55","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.694","volume":"5","author":"X Ou","year":"2024","unstructured":"Ou X, Gao G, Habaz IA, Wang Y. Mechanisms of resistance to tyrosine kinase inhibitor-targeted therapy and overcoming strategies. MedComm. 2024;5:e694.","journal-title":"MedComm"},{"key":"3901_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2024.101176","volume":"78","author":"D Wu","year":"2025","unstructured":"Wu D, Sun Q, Tang H, Xiao H, Luo J, Ouyang L, et al. Acquired resistance to tyrosine kinase targeted therapy: mechanism and tackling strategies. Drug Resist Updates. 2025;78:101176.","journal-title":"Drug Resist Updates"},{"key":"3901_CR57","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.pccm.2024.08.002","volume":"2","author":"J Zhang","year":"2024","unstructured":"Zhang J, Vokes N, Li M, Xu J, Bai H, Wang J, et al. Overcoming EGFR-TKI resistance by targeting the tumor microenvironment. Chin Med J Pulm Crit Care Med. 2024;2:151\u201361.","journal-title":"Chin Med J Pulm Crit Care Med"},{"key":"3901_CR58","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/s41416-019-0573-8","volume":"121","author":"A Leonetti","year":"2019","unstructured":"Leonetti A, Sharma S, Minari R, Perego P, Giovannetti E, Tiseo M. Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer. Br J Cancer. 2019;121:725\u201337.","journal-title":"Br J Cancer"},{"key":"3901_CR59","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41580-025-00873-w","volume":"27","author":"M Radulovic","year":"2025","unstructured":"Radulovic M, Yang C, Stenmark H. Lysosomal membrane homeostasis and its importance in physiology and disease. Nat Rev Mol Cell Biol. 2025;27:71\u201387.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"3901_CR60","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1042\/EBC20160005","volume":"60","author":"P Jackson Matthew","year":"2016","unstructured":"Jackson Matthew P, Hewitt Eric W. Cellular proteostasis: degradation of misfolded proteins by lysosomes. Essays Biochem. 2016;60:173\u201380.","journal-title":"Essays Biochem"},{"key":"3901_CR61","doi-asserted-by":"publisher","unstructured":"Shan KS, Musleh Ud Din S, Dalal S, Gonzalez T, Dalal M, Ferraro P et al. Bispecific Antibodies in Solid Tumors: Advances and Challenges. Int J Mol Sci. 2025; https:\/\/doi.org\/10.3390\/ijms26125838.","DOI":"10.3390\/ijms26125838"},{"key":"3901_CR62","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1093\/abt\/tbaf012","volume":"8","author":"C Wang","year":"2025","unstructured":"Wang C, Huang H, Song Z, Li Z, Huang J, Cao L, et al. A novel bispecific antibody CVL006 superior to AK112 for dual targeting of PD-L1 and VEGF in cancer therapy. Antib Therapeut. 2025;8:189\u201396.","journal-title":"Antib Therapeut"},{"key":"3901_CR63","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2024.111722","volume":"28","author":"T Zhong","year":"2025","unstructured":"Zhong T, Zhang L, Huang Z, Pang X, Jin C, Liu W, et al. Design of a fragment crystallizable-engineered tetravalent bispecific antibody targeting programmed cell death-1 and vascular endothelial growth factor with cooperative biological effects. iScience. 2025;28:111722.","journal-title":"iScience"},{"key":"3901_CR64","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2023.2180794","volume":"15","author":"X Pang","year":"2023","unstructured":"Pang X, Huang Z, Zhong T, Zhang P, Wang ZM, Xia M, et al. Cadonilimab, a tetravalent PD-1\/CTLA-4 bispecific antibody with trans-binding and enhanced target binding avidity. mAbs. 2023;15:2180794.","journal-title":"mAbs"},{"key":"3901_CR65","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.2165\/00003495-200767170-00008","volume":"67","author":"SKA Blick","year":"2007","unstructured":"Blick SKA, Scott LJ. Cetuximab. Drugs. 2007;67:2585\u2013607.","journal-title":"Drugs"},{"key":"3901_CR66","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-5481-z","volume":"19","author":"B Zheng","year":"2019","unstructured":"Zheng B, Wang X, Wei M, Wang Q, Li J, Bi L, et al. First-line cetuximab versus bevacizumab for RAS and BRAF wild-type metastatic colorectal cancer: a systematic review and meta-analysis. BMC Cancer. 2019;19:280.","journal-title":"BMC Cancer"},{"key":"3901_CR67","doi-asserted-by":"crossref","unstructured":"Jonker DJ, O\u2019Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au H-J et al. Cetuximab for the Treatment of Colorectal Cancer. New Engl J Med. 357:2040\u20138.","DOI":"10.1056\/NEJMoa071834"},{"key":"3901_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2021.103424","volume":"164","author":"E Muraro","year":"2021","unstructured":"Muraro E, Fanetti G, Lupato V, Giacomarra V, Steffan A, Gobitti C, et al. Cetuximab in locally advanced head and neck squamous cell carcinoma: Biological mechanisms involved in efficacy, toxicity and resistance. Crit Rev Oncol Hematol. 2021;164:103424.","journal-title":"Crit Rev Oncol Hematol"},{"key":"3901_CR69","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1038\/s41586-022-05235-6","volume":"610","author":"H Marei","year":"2022","unstructured":"Marei H, Tsai W-TK, Kee Y-S, Ruiz K, He J, Cox C, et al. Antibody targeting of E3 ubiquitin ligases for receptor degradation. Nature. 2022;610:182\u20139.","journal-title":"Nature"},{"key":"3901_CR70","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1021\/jacs.0c10008","volume":"143","author":"AD Cotton","year":"2021","unstructured":"Cotton AD, Nguyen DP, Gramespacher JA, Seiple IB, Wells JA. Development of Antibody-Based PROTACs for the Degradation of the Cell-Surface Immune Checkpoint Protein PD-L1. J Am Chem Soc. 2021;143:593\u20138.","journal-title":"J Am Chem Soc"},{"key":"3901_CR71","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-44533-z","volume":"15","author":"GD Lewis","year":"2024","unstructured":"Lewis GD, Li G, Guo J, Yu S-F, Fields CT, Lee G, et al. The HER2-directed antibody-drug conjugate DHES0815A in advanced and\/or metastatic breast cancer: preclinical characterization and phase 1 trial results. Nat Commun. 2024;15:466.","journal-title":"Nat Commun"},{"key":"3901_CR72","doi-asserted-by":"publisher","first-page":"3022","DOI":"10.1200\/JCO.2025.43.16_suppl.3022","volume":"43","author":"D Liu","year":"2025","unstructured":"Liu D, Liu B, Li Z, Gao B, Zhang X, Ruan J, et al. A pooled analysis of JSKN003, a biparatopic anti-HER2 antibody conjugate (ADC), in patients with advanced HER2-overexpressing (IHC 3+) gastrointestinal tumors. J Clin Oncol. 2025;43:3022.","journal-title":"J Clin Oncol"},{"key":"3901_CR73","doi-asserted-by":"publisher","unstructured":"Wang T-H, Wu C-C, Huang K-Y, Leu Y-L, Yang S-C, Chen C-L et al. Integrated Omics Analysis of Non-Small-Cell Lung Cancer Cells Harboring the EGFR C797S Mutation Reveals the Potential of AXL as a Novel Therapeutic Target in TKI-Resistant Lung Cancer. Cancers 2021; https:\/\/doi.org\/10.3390\/cancers13010111.","DOI":"10.3390\/cancers13010111"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03901-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03901-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03901-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T22:04:32Z","timestamp":1787004272000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03901-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,16]]},"references-count":73,"journal-issue":{"issue":"34","published-print":{"date-parts":[[2026,9,8]]}},"alternative-id":["3901"],"URL":"https:\/\/doi.org\/10.1038\/s41388-026-03901-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8437918\/v1","asserted-by":"object"}]},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,16]]},"assertion":[{"value":"23 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"All animal experiments complied with relevant ethical regulations and were approved by the Committee for Animal Welfare at Zhejiang University (ZJU20220455).","order":2,"name":"Ethics","label":"Ethics statement","group":{"name":"EthicsHeading","label":"Ethics"}}]}}